Apollo Therapeutics Announces Second Close of Series C Financing Bringing Total Raised in Round to $260 Million
January 02, 2024 02:00 AM Eastern Standard Time CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Apollo Therapeutics (“Apollo” or “the Company”), a portfolio biopharmaceutical company focused on translating fundamental medical research into medicines through a hub-and-spoke approach, today…